General
Preferred name
ASUNAPREVIR
Synonyms
BMS-650032 ()
BMS 650032 ()
Sunvepra ()
BMS650032 ()
P&D ID
PD073711
CAS
630420-16-5
Tags
available
drug
Approved by
PMDA
First approval
2014
Drug indication
Hepatitis C virus infection
Drug Status
withdrawn
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Asunaprevir (BMS-650032) is an orally bioavailable, oligopeptide-based inhibitor of the nonstructural protein 3 (NS3), from hepatitis C virus (HCV) . NS3, is a serine protease that is essential for proteolytic cleavages within the HCV polyprotein, a function that is key during HCV viral RNA replication. More recently asunaprevir has been reported to inhibit the papain-like protease (PL-pro, nsp3) in a number of coronaviruses . (GtoPdb)
INDICATION Asunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis C in adult patients with hepatitis C virus genotypes 1 or 4 and compensated liver cirrhosis.[L2278] ; ; Hepatitis C is a liver disease caused by the hepatitis C virus. The chronic state of this condition accounts for 60-80% of the cases from which the risk of cirrhosis of the liver within 20 years is of around 15-30%.[L2281] The genotype 1 is the most common type of hepatitis C in the United States and the most difficult to treat.[L2282]
PHARMACODYNAMICS Studies in vitro demonstrated a significant antiviral activity in HCV replicon cell systems with an EC50 of 4nm and 1nm against the HCV genotype 1a and 1b respectively.[A32528] These studies showed a limited activity against the genotypes 2 and 3. This property makes asunaprevir a highly selective anti-HCV agent that is not effective against HCV closely related virus.[A18434] Asunaprevir produce robust declines in HCV RNA levels in patients with HCV genotype 1 infection.[A32527]In clinical studies, it has been shown that asunaprevir is well-tolerated and the mean maximum HCV RNA level reduction from baseline was of approximately 2.87 log10 IU/ml.[A32528]; ; Monotherapy clinical studies with asunaprevir showed a mean maximum decline of HCV RNA in the range of 0.28-2.87 log10 IU/ml when administered in increasing doses from 10-600 mg. When asunaprevir was used as a combination product, it was possible to obtain a sustained virological response (aviremia 24 weeks after completion of therapy) in 83-92% of the patients.[A18434]
Cell lines
0
Organisms
1
Compound Sets
12
ChEMBL Approved Drugs
CHEMBL2105735
ChEMBL Drugs
CHEMBL2105735
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB11586
DrugBank Approved Drugs
DB11586
DrugCentral
4889
DrugCentral Approved Drugs
4889
DrugMAP
DMQI43G
Guide to Pharmacology
10882
MedChem Express Bioactive Compound Library
HY-14434
TargetMol Bioactive Compound Library
T4474
External IDs
30
Properties
(calculated by RDKit )
Molecular Weight
747.27
Hydrogen Bond Acceptors
10
Hydrogen Bond Donors
3
Rotatable Bonds
11
Ring Count
5
Aromatic Ring Count
2
cLogP
3.85
TPSA
182.33
Fraction CSP3
0.57
Chiral centers
5.0
Largest ring
6.0
QED
0.29
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Proteases/Proteasome
Anti-infection
Metabolic Enzyme/Protease
Target
HCV NS3/4A protease
HCV
HCV Protease
SARS-CoV
MOA
HCV Protease inhibitor
HCV inhibitor
Source data